|

V940 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Intismeran Autogene, mRNA-4157

Pipeline

Phase 2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Cancer2
  • Squamous Non-small-cell Lung Cancer1
  • Malignant Melanoma1
  • Lung Cancer1

Springdale, Arkansas1 trial

A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Highlands Oncology Group ( Site 4042)

Phase 2

Paramus, New Jersey1 trial

A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Valley Health Systems - Ridgewood Campus ( Site 0010)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.